Catalyst Funds Management’s Regenxbio RGNX Stock Holding History

Catalyst Funds Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,400	Closed	-$35.7K	–	1067
2024 Q3	$35.7K	Buy	+3,400	New	+$41.4K	0.01%	920

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Funds Management's RGNX Position: Q4 2024 in Review

Catalyst Funds Management sold out of Regenxbio (RGNX) in Q4 2024, closing a stake of 3,400 shares — an estimated $35.7K sold.

Catalyst Funds Management first reported a position in RGNX in Q3 2024 and held it in 1 quarter. The position peaked at $35.7K in Q3 2024. 177 funds tracked by Wall St. Rank hold RGNX as of Q4 2024.

Catalyst Funds Management reported no remaining Regenxbio position as of Q4 2024 after selling out during the quarter.
Catalyst Funds Management sold 3,400 Regenxbio shares in Q4 2024, an estimated $35.7K.
Catalyst Funds Management first reported a position in Regenxbio in Q3 2024 and held it in 1 quarter.
Catalyst Funds Management's Regenxbio position peaked at $35.7K in Q3 2024.
177 funds tracked by Wall St. Rank held Regenxbio as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.